Form 4: Denali Director Nancy Thornberry Receives Equity Awards

Director Nancy Thornberry was granted 6,408 restricted stock units and 19,226 stock options as part of her annual compensation package.

Summary

• Nancy Thornberry, a member of the Board of Directors, received two separate equity grants on June 3, 2026.
• The first grant consists of 6,408 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of common stock.
• The second grant consists of 19,226 stock options with an exercise price of $19.66 per share.
• Both the RSUs and the stock options are scheduled to vest in full on the earlier of June 3, 2027, or the day before the next annual meeting of stockholders.
• Following these transactions, Thornberry directly owns 31,125 shares of common stock, which includes the newly granted unvested RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing. While equity alignment is positive, it is a standard part of director compensation and does not signal a change in company fundamentals.

Positives

• Director compensation is heavily weighted toward equity, aligning board interests with long-term shareholder value.
• The stock options have a 10-year term, expiring on June 3, 2036, suggesting a long-term commitment to the company's growth.
• The exercise price of $19.66 provides a clear baseline for the director to realize value only if the stock price appreciates.

Negatives

• The issuance of 25,634 new equity-linked instruments contributes to the overall dilution of existing shareholders.
• The vesting period is relatively short at only one year, which is standard for directors but provides less long-term 'lock-in' than executive grants.

Risks

• The value of the stock options is entirely dependent on the market price exceeding $19.66; if the price remains below this level, the options will expire worthless.
• Vesting is contingent upon continued service on the board, posing a minor risk to the director's total compensation if she departs early.

Future Outlook

The grants are part of a standard annual compensation program for non-employee directors, intended to ensure continued board stability and alignment with corporate performance through 2027.

Industry Context

StockSavvy.ai notes that in the biotechnology sector, equity-heavy compensation for directors is a standard practice to conserve cash for research and development while incentivizing board members to oversee long-term clinical and regulatory milestones.

Comparison to Industry Standards

• The mix of RSUs and stock options is consistent with compensation structures at peer biotechnology companies like Sage Therapeutics and Alnylam Pharmaceuticals.
• A one-year cliff vesting for director grants is the prevailing standard among NASDAQ-listed life sciences companies.
• The 10-year option term is a standard duration for incentive stock options in the U.S. market.

Corporate Governance

Stakeholder Impact

• Shareholders will experience a minor dilutive effect when the RSUs vest and options are exercised.
• The director is incentivized to maintain or improve the company's market valuation.

Next Steps

• Vesting of the RSUs and options on the one-year anniversary or the next annual meeting.
• Potential future Form 4 filings if the director sells shares or receives further grants.

Key Dates

Recommendation

This filing is a routine disclosure of director compensation and does not contain new material information regarding the company's clinical pipeline, financial results, or strategic direction that would justify a change in investment rating.

Keywords

Denali Therapeutics, DNLI, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Nancy Thornberry, Director Compensation, Biotechnology